A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial. The vaccine – developed by researchers at the ...

CureVac has done well to continue to develop the use of its CVGBM shared off-the-shelf vaccine candidate for the treatment of patients with resectable GBM. It has already been able to do well in ...

Glioblastoma multiforme (GBM) is associated with a poor ... to assess the safety and immunogenicity of a dendritic cell-based vaccine targeting the EGFRvIII antigen. The study included patients ...

In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine developed at the University of Florida quickly reprogrammed the immune system to attack glioblastoma ...

More information: Carla Bianca Luena Victorio et al, Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells ...

Glioblastoma (GBM) is a fast growing and aggressive ... neurosurgeon Robert Fenstermaker began their work on the SurVaxM vaccine at Roswell Park Comprehensive Cancer Center. Ciesielski and ...